Plus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Rhea-AI Summary

Plus Therapeutics (NASDAQ:PSTV), a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system (CNS) cancers, will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025.

The company's President and CEO, Marc H. Hedrick, M.D., will engage in a fireside chat with H.C. Wainwright's VP of Equity Research, Sean Lee. The discussion will be available on demand starting September 5, 2025, at 7:00 AM ET for registered conference attendees.

News Market Reaction

+7.60%

10 alerts

+7.60% News Effect

+11.8% Peak Tracked

-8.5% Trough Tracked

+$3M Valuation Impact

$47M Market Cap

0.6x Rel. Volume

On the day this news was published, PSTV gained 7.60%, reflecting a notable positive market reaction. Argus tracked a peak move of +11.8% during that session. Argus tracked a trough of -8.5% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $3M to the company's valuation, bringing the market cap to $47M at that time.

Data tracked by StockTitan Argus on the day of publication.

HOUSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces that it will participate in the H.C. Wainwright 27^th Annual Global Investment Conference. The conference is being held on September 8 – 10, 2025 at the Lotte New York Palace Hotel.

Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer will participate in a fireside chat with Sean Lee, VP of Equity Research at H.C. Wainwright. The fireside chat will be available on demand beginning Friday, September 5 at 7:00am ET for registered investors of the conference. To request a one-on-one meeting with Dr. Hedrick and to register for the conference, click below:
https://hcwevents.com/annualconference/

About Plus Therapeutics
Headquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. For more information, visit https://plustherapeutics.com/.

Investor Contact
CORE IR
investor@plustherapeutics.com

FAQ

When is Plus Therapeutics (PSTV) presenting at the H.C. Wainwright Conference 2025?

The fireside chat will be available on demand starting September 5, 2025, at 7:00 AM ET. The conference runs from September 8-10, 2025 at the Lotte New York Palace Hotel.

Who will represent Plus Therapeutics (PSTV) at the H.C. Wainwright Conference?

Marc H. Hedrick, M.D., Plus Therapeutics' President and Chief Executive Officer, will participate in a fireside chat with Sean Lee, VP of Equity Research at H.C. Wainwright.

What is Plus Therapeutics' (PSTV) main business focus?

Plus Therapeutics is a clinical-stage pharmaceutical company that develops targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers.

How can investors access Plus Therapeutics' (PSTV) presentation at the H.C. Wainwright Conference?

Investors must register for the conference at hcwevents.com/annualconference to access the on-demand fireside chat. One-on-one meetings with Dr. Hedrick can also be requested through registration.